Press release -

Atherosclerosis vaccine study wins VINNOVA grant

Athera Biotechnologies has been granted support from the Swedish Governmental Agency for Innovation Systems, VINNOVA, for a pre-study to investigate a new approach with vaccination to prevent atherosclerosis.

Three hundred companies had applied for the current call to the Research&Growth program to a total amount of SEK 440 million. VINNOVA has today announced the 49 companies of these 300 which are supported with in total SEK 50 million. Athera Biotechnologies is among the seven grant winners who are involved in the life science industry.

Through the Research&Growth program, VINNOVA finances research and development projects in small companies. Companies can apply for support for research and development projects, pre clinical trials or necessity identification before research and development projects.


  • Health, Health Care, Pharmaceuticals


  • athera biotechnologies
  • athera
  • atherosclerosis
  • läkemedel

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of cardiovascular disease. Athera´s focus is on ATH3G10, a clinical stage biopharmaceutical program with block-buster potential. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information:


Carina Schmidt

Press contact Senior Business Advisor, M.Sc. Senior Business Advisor, M.Sc. +46 (0)76-1938190

Related content